ISMRM & SMRT Annual Meeting • 15-20 May 2021

2021 ISMRM & SMRT Annual Meeting Logo Graphic

Member-Initiated Symposium

How to Benchmark Your Cancer Biomarker for the Clinic

Navigation: Back to Meeting HomeBack to Meeting Home Navigation: Back to Program-at-a-GlanceBack to the Program-at-a-Glance

How to Benchmark Your Cancer Biomarker for the Clinic
Member-Initiated Symposium
Tuesday, 18 May 2021
Concurrent 8 14:00 -  16:00 Moderators: Laura Bell & Janine Lupo
Session Number: MIS-12
Parent Session: How to Benchmark Your Cancer Biomarker for the Clinic

Session Number:MIS-12

Laura Bell, Janine Lupo

This Symposium was proposed by the MR of Cancer study group. Clinical biomarkers are an important component of cancer diagnosis, the determination of treatment, and response assessment for improved patient care. In this proposed symposium, the MR Cancer study group aims to outline the complete process of benchmarking cancer biomarkers for widespread clinical adoption. Before translating quantitative imaging biomarkers into clinical trials, it is vital to standardize and evaluate their performance under diverse conditions in order to determine clinical readiness at distinct junctures in the course of their development. For this symposium, we have invited 5 speakers to give 20-minute talks on their personal experiences in developing and benchmarking clinical biomarkers. The first talk will start with an overview of the importance and the multiple stages of benchmarking. The remaining presentations will each focus on a phase of the benchmarking process: basic benchmarking (evaluating systematic variations using phantoms and healthy volunteers), benchmarking for novel MR sequences, benchmarking for software analysis tools, and finally the success of biomarkers out of clinical trials and into clinical practice.

Target Audience
Cancer imaging researchers who are interested in translating novel methodologies, biomarkers, and image analysis tools into the clinic.

Educational Objectives
As a result of attending this course, participants should be able to:
Upon completion of this course, participants should be able to: - Describe the spectrum of benchmarking from initial experiments in animals and phantoms to routine clinical use; - Identify the systematic challenges associated with benchmarking and ongoing standardization efforts to minimize variation; and - Explain the validation process for a biomarker and image processing tool to become approved for routine clinical use and give an example of each.

    Overview of Benchmarking for Clinical Translation: From Technique Development to Clinical Tool
Michael Boss
American College of Radiology
    Benchmarking: Back to Basics
Kathryn Keenan
National Institute of Standards & Technology
    Technical Benchmarking & Standardization of Novel Diffusion-Based Biomarker Technologies
Thomas Chenevert
University of Michigan
    Technical Benchmarking for Image Analysis/Prediction Tools
Jayashree Kalpathy-Cramer
Massachusetts General Hospital, Harvard Medical School
    From Clinical Trials to Clinical Use: Neuro-Oncologic Imaging
Benjamin Ellingson
University of California, Los Angeles

Back to Meeting Home   |   Back to Top

The International Society for Magnetic Resonance in Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.